Form 8-K - Current report:
SEC Accession No. 0001628280-23-000057
Filing Date
2023-01-03
Accepted
2023-01-03 13:41:40
Documents
12
Period of Report
2022-12-30
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K aqst-20221230.htm   iXBRL 8-K 35242
  Complete submission text file 0001628280-23-000057.txt   175076

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20221230.xsd EX-101.SCH 1893
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20221230_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20221230_pre.xml EX-101.PRE 13037
6 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20221230_htm.xml XML 11254
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38599 | Film No.: 23501461
SIC: 2834 Pharmaceutical Preparations